Can HPLC really detect every peptide impurity? Not always. Our latest guide explains peptide impurities not detected by HPLC, including co-eluting impurities, chiral variants, deamidation, isobaric sequence changes, aggregates, counterions, moisture and residual solvents. Learn how to interpret peptide HPLC chromatograms, identify COA red flags, understand HPLC purity versus peptide identity, and discover when LC-MS/MS, HRMS, SEC, ICP-MS and other orthogonal testing methods may be necessary. Explore this practical guide from OasBioScience and make more informed decisions when evaluating peptide analytical data

Peptide Impurities Not Detected by HPLC: Why the Number Can Mislead

https://pubmed.ncbi.nlm.nih.gov/

Peptide impurities not detected by HPLC are one of the most misunderstood subjects in peptide quality control.

A researcher may receive a Certificate of Analysis showing:

HPLC purity: 99.0%

At first glance, that looks excellent.

But what does the 99.0% actually mean?

It does not automatically mean that 99% of the material inside the vial is the correct, intact peptide molecule.

That distinction is extremely important.

Reversed-phase high-performance liquid chromatography with UV detection, commonly called RP-HPLC-UV, is one of the most useful analytical tools available for evaluating peptide-related purity.

However, HPLC is a separation and detection technique.

It is not a universal identity test.

It does not automatically determine molecular structure.

It does not automatically quantify every substance inside a vial.

And it cannot guarantee that every impurity will produce a separate, visible peak.

This is where researchers need to understand the concept of peptide impurities not detected by HPLC.

Some impurities can:

• Co-elute with the desired peptide.
• Have almost identical chromatographic behavior.
• Remain strongly bound to the column.
• Produce little or no UV response.
• Have the same molecular mass as another sequence variant.
• Exist as structural isomers.
• Appear beneath the main chromatographic peak.
• Remain in the vial as water or counterions.
• Require a completely different analytical separation mechanism.

Regulatory and pharmaceutical analytical research recognizes this challenge. The FDA has specifically investigated peptide impurity characterization using LC-MS/MS and high-resolution mass spectrometry because conventional chromatographic approaches may not fully resolve or identify peptide-related impurities. In one FDA investigation of marketed salmon calcitonin products, more than 120 peptide impurities were identified using LC-MS/MS-based approaches.

That does not make HPLC unimportant.

It means HPLC should be interpreted correctly.

The best question is not:

“Does this peptide have 99% HPLC purity?”

The better question is:

“What exactly did the analytical method measure, and what could the method have missed?”

What Does HPLC Actually Measure?

To understand peptide impurities not detected by HPLC, we first need to understand what an HPLC purity percentage represents.

In a typical RP-HPLC-UV method, the peptide sample is injected into a chromatographic system.

The compounds interact differently with the stationary phase and mobile phase.

They separate according to their chromatographic behavior.

The detector then measures UV absorbance.

For peptide analysis, detection around 214 nm is commonly useful because peptide bonds absorb strongly in this region.

The instrument produces a chromatogram.

Each detected component may appear as a peak.

The software integrates the peaks and calculates their relative areas.

For example:

Component	Relative Peak Area
Main peptide peak	99.0%
Impurity A	0.5%
Impurity B	0.3%
Impurity C	0.2%

This may be reported as approximately 99% HPLC purity.

But there is a critical limitation.

The instrument only calculates what the analytical method separates and detects.

If two compounds elute together, they can appear as one peak.

If a substance has weak UV response, it may contribute little to the chromatogram.

If an aggregate never reaches the detector, it cannot contribute to the detected peak area.

If a material remains in the vial as water or counterion, it is not represented as a peptide impurity peak in the same way.

This is why the phrase peptide impurities not detected by HPLC should not be interpreted as “HPLC cannot detect impurities.”

It means that HPLC has analytical blind spots.

Purity Is Not the Same as Identity

One of the biggest mistakes I see researchers make is treating purity and identity as interchangeable concepts.

They are not.

What Does Peptide Purity Mean?

Purity asks:

How much of the detected chromatographic material corresponds to the principal peak under the specified analytical conditions?

Identity asks:

Is that principal peak actually the intended molecular structure?

These are different questions.

Imagine ordering a specific peptide sequence.

The HPLC produces one large peak.

That peak may be extremely clean chromatographically.

But another peptide with similar chromatographic behavior could potentially appear in the same region.

HPLC retention time alone is therefore not sufficient proof of molecular identity.

FDA guidance similarly notes that identification based solely on a single chromatographic retention time is not considered specific enough for many analytical purposes; combinations such as HPLC/UV with mass spectrometry or orthogonal chromatographic approaches provide greater specificity.

A simple analogy

Think of HPLC purity as looking through a window and seeing a clear liquid.

You know the liquid is visually clean.

But you do not necessarily know what the liquid chemically is.

Mass spectrometry is closer to checking its molecular fingerprint.

That is why a strong peptide characterization strategy combines different analytical principles.

9 Peptide Impurities Not Detected by HPLC

Now we can examine the major categories of peptide impurities not detected by HPLC or not adequately characterized by conventional RP-HPLC-UV.

1. Co-Eluting Peptide Impurities

One of the most important examples of peptide impurities not detected by HPLC is a co-eluting impurity.

Co-elution occurs when two or more chemical species pass through the chromatographic system at essentially the same time.

The chromatogram may display one apparently clean peak.

But that peak can contain more than one molecular species.

This is especially important when the impurity has similar:

• Hydrophobicity.
• Charge.
• Molecular size.
• Amino-acid composition.
• Sequence characteristics.
• Interaction with the C18 stationary phase.

The chromatogram may therefore look excellent while the underlying sample is more complicated.

Why Does Co-Elution Matter?

Imagine a main peptide representing 97% of a sample and a structurally related impurity representing 3%.

If both compounds co-elute perfectly, the detector can see a single combined peak.

The report may therefore describe the material as having a single dominant peak.

The impurity has not necessarily disappeared.

It has simply become analytically inseparable under that particular method.

This is one reason FDA research has emphasized LC-MS/MS and orthogonal analytical approaches for peptide impurity characterization. FDA researchers have specifically reported that LC-MS/MS approaches can screen impurities that co-elute with the API peak.

How to investigate co-elution

Useful approaches can include:

• LC-MS.
• LC-HRMS.
• LC-MS/MS.
• Alternative chromatographic columns.
• Different gradient conditions.
• HILIC.
• Ion-exchange chromatography.
• Targeted peptide mapping.

The correct method depends on the peptide and the suspected impurity.

2. Chiral Inversion and D-Amino-Acid Variants

Another difficult category involves chiral impurities.

Amino acids are inherently stereochemically important.

During peptide synthesis, racemization or epimerization can occur under certain conditions.

An L-amino acid residue can potentially become its D-counterpart.

The resulting peptide may have:

• Almost identical elemental composition.
• The same molecular weight.
• Similar hydrophobicity.
• Similar UV absorbance.
• Similar RP-HPLC retention behavior.

That creates an analytical challenge.

A conventional achiral C18 RP-HPLC method may not provide adequate separation.

The resulting D-amino-acid-containing peptide may therefore become one of the peptide impurities not detected by HPLC in the practical sense that it is not resolved as an independent peak.

How Can Researchers Investigate Chiral Variants?

Potential approaches include:

• Chiral chromatography.
• Chiral amino-acid analysis.
• Marfey-type derivatization.
• Advanced LC-MS/MS.
• Targeted fragmentation strategies.

This is particularly important when sequence stereochemistry matters to biological activity.

The key lesson is simple:

Same mass does not necessarily mean same structure.

And:

Same retention time does not necessarily mean same molecule.

3. Deamidation and IsoAsp Formation

Deamidation is another important source of peptide impurities not detected by HPLC.

Asparagine and glutamine residues can undergo chemical modifications during manufacturing, processing, or storage.

Asparagine deamidation can generate aspartate and isoaspartate products.

The chemical change may be relatively small in mass but potentially important structurally.

Isoaspartate formation is particularly interesting because the peptide backbone can be altered.

The result may retain very similar chromatographic behavior under a conventional RP-HPLC method.

Why Is Deamidation Difficult?

A standard HPLC chromatogram may show one dominant peak.

Yet the peak can contain:

• Native peptide.
• Deamidated peptide.
• Isoaspartyl peptide.

If the chromatographic method does not separate those species adequately, the impurity becomes part of the apparent main peak.

The mass difference caused by deamidation is approximately +0.984 Da.

That means conventional low-resolution MS may also require careful interpretation.

High-resolution MS, MS/MS, specialized separations, and targeted structural methods can provide much more information.

FDA guidance on product-related impurities recognizes deamidated and other modified peptide forms as degradation variants requiring appropriate analytical characterization.

Why This Matters

A peptide can therefore look chemically clean under one method while containing a structurally altered subpopulation.

That is exactly why peptide impurities not detected by HPLC deserve attention when studying peptide stability.

4. Isobaric Sequence Variants

Isobaric means that two different molecular structures can have the same nominal mass.

This creates another major limitation.

A classic analytical challenge involves amino acids such as leucine and isoleucine.

They have the same molecular mass.

A simple mass measurement therefore cannot necessarily tell you which residue is present at a particular position.

Likewise, certain sequence alterations can produce closely related masses and very similar chromatographic behavior.

A peptide containing a sequence substitution may therefore escape straightforward identification.

Why HPLC Alone Is Not Enough

HPLC separates according to chemical interaction.

It does not read the peptide sequence letter by letter.

Mass spectrometry provides molecular-mass information.

But even mass alone can have limitations.

For some sequence questions, researchers need tandem mass spectrometry and appropriate fragmentation strategies.

Advanced techniques such as ETD or ECD can sometimes provide useful sequence-localization information.

USP research on synthetic peptide reference standards specifically highlights the need for additional analytical techniques when dealing with chiral or isobaric amino acids.

This is another reason that peptide impurities not detected by HPLC cannot be understood from a purity percentage alone.

5. Aggregates and Oligomers

Aggregation is particularly important for longer, hydrophobic, or structurally unstable peptides.

Peptide molecules can associate to form:

• Dimers.
• Oligomers.
• Higher-order aggregates.
• Insoluble particles.
• Fibrillar structures.

Some aggregates may not behave like individual peptide molecules during RP-HPLC.

They may interact strongly with the column.

In severe cases, strongly retained material may not elute under the analytical conditions.

If material does not reach the detector, it cannot be included normally in the calculated chromatographic peak area.

This creates a potentially serious blind spot.

How Should Aggregates Be Investigated?

Depending on the peptide and purpose, researchers may consider:

• SEC.
• SEC-MALS.
• Analytical ultracentrifugation.
• Dynamic light scattering.
• Electron microscopy in specialized investigations.
• Other validated aggregation assays.

FDA guidance recognizes aggregates as an important product-related category and identifies size-exclusion chromatography among techniques that can be used for aggregate assessment.

For long or aggregation-prone peptides, a single RP-HPLC result should therefore not be treated as a complete aggregation assessment.

6. Counterions, Water and Non-Chromophoric Materials

One of the most important distinctions between HPLC purity and actual peptide content involves non-peptide material in the vial.

Synthetic peptides are frequently isolated as salts.

Examples include:

• TFA salts.
• Acetate salts.
• Other counterions.

Lyophilized material can also contain residual water.

These materials are not necessarily represented as ordinary peptide impurity peaks in a UV chromatogram.

Therefore:

99% HPLC purity does not automatically mean 99% peptide by dry vial mass.

This is an extremely important point for researchers preparing solutions based on mass.

A vial labeled “10 mg peptide” may not contain 10 mg of chemically pure, anhydrous, counterion-free peptide.

The actual peptide content requires appropriate quantitative characterization.

Why This Matters for Experimental Calculations

If a researcher assumes that every milligram on the label is active peptide mass, the calculated molar concentration can be wrong.

This can affect:

• Experimental dosing calculations.
• Concentration comparisons.
• Assay reproducibility.
• Structure-activity studies.
• Peptide-to-peptide comparisons.

USP work on synthetic peptide reference standards describes the use of multiple analytical measurements and mass-balance approaches when assigning quantitative values to lyophilized peptide materials.

7. Residual Solvents

Residual solvents are another category that a peptide HPLC purity number does not necessarily answer.

Peptide manufacturing and purification can involve organic solvents.

Examples may include:

• Acetonitrile.
• DMF.
• Other synthesis or purification solvents.

Whether and how these are detected depends on the analytical method.

A UV chromatogram designed primarily to measure peptide-related peaks should not automatically be interpreted as a complete residual-solvent analysis.

What Should Be Used?

Gas chromatography, often coupled with mass spectrometry when appropriate, can be useful for volatile or semi-volatile residual solvents.

The exact analytical method should be selected according to:

• Solvent.
• Matrix.
• Expected concentration.
• Applicable specification.
• Intended research use.

This is another reason why the phrase peptide impurities not detected by HPLC extends beyond peptide sequence variants.

Some impurities simply require a different analytical technology.

8. Oxidation and Other Degradation Products

Peptides can undergo chemical degradation.

Common modification pathways can include:

• Oxidation.
• Deamidation.
• Hydrolysis.
• Isomerization.
• Disulfide-related changes in cysteine-containing peptides.
• Other sequence or side-chain modifications.

Methionine oxidation is one well-known example.

Depending on the analytical conditions, an oxidized species may be separated from the native peptide.

But separation is not guaranteed.

If it co-elutes, its presence may not be obvious from a simple purity percentage.

Why Stability Testing Matters

A peptide can pass an HPLC test at the time of manufacture and change during storage.

Therefore, researchers should distinguish between:

Release testing

and

stability-indicating testing.

A meaningful stability program should evaluate whether degradation products appear or increase over time.

FDA guidance specifically emphasizes that degradation products arising during manufacture or storage should be tested and monitored using appropriate analytical procedures.

9. Truncated and Deletion Sequences

Peptide synthesis involves multiple chemical steps.

Each coupling step introduces the possibility of incomplete reactions.

That can produce:

• Deletion sequences.
• Truncated peptides.
• Incomplete coupling products.
• Modified side products.

Many of these can be separated by RP-HPLC.

But not every impurity will necessarily be completely resolved.

Some may overlap with the main peak or with other impurity peaks.

This becomes increasingly important as peptide length and structural complexity increase.

Longer peptides generally provide more opportunities for sequence-related impurities to form.

That is why peptide characterization becomes increasingly dependent on orthogonal analytical methods as molecular complexity increases.

The Difference Between HPLC Purity and Net Peptide Content

This distinction deserves its own section because it is one of the most common sources of confusion.

Suppose a vial contains 10 mg of lyophilized material.

The HPLC report says:

99% purity.

That does not necessarily mean:

9.9 mg of pure peptide.

Why?

Because HPLC peak-area purity and total material composition are different measurements.

The vial may also contain:

• Water.
• Counterions.
• Residual solvents.
• Other non-UV-detected material.

A more comprehensive quantitative assessment may involve:

• HPLC.
• Moisture analysis.
• Counterion analysis.
• Appropriate mass-balance calculations.

This is sometimes described through the concept of net peptide content (NPC).

The exact calculation should be based on validated analytical data rather than assuming universal percentages for every peptide.

That point is important.

Water content and counterion content vary significantly among materials.

Therefore, researchers should not blindly subtract a fixed percentage from every vial.

How to Read a Peptide HPLC Chromatogram

If you receive a peptide COA, do not immediately jump to the bold “Purity” number.

Look at the chromatogram.

1. Is the Raw Chromatogram Provided?

A COA that says:

Purity: 99.2%

without showing the chromatogram gives you limited information.

The chromatogram lets you examine:

• Peak shape.
• Baseline.
• Retention time.
• Shoulders.
• Secondary peaks.
• Tailing.
• Integration.

2. Is the Main Peak Symmetrical?

A strongly distorted peak deserves investigation.

Look for:

• Shoulders.
• Splitting.
• Excessive tailing.
• Broadening.
• Irregular baseline return.

A shoulder does not automatically prove an impurity.

But it can justify additional investigation.

3. Are Visible Peaks Actually Integrated?

This is important.

If you see a visible secondary peak but the summary table reports only the main peak, ask why.

Potential explanations include:

• Integration threshold.
• Baseline selection.
• Method design.
• Signal-to-noise limitations.
• Legitimate analytical exclusion.

The correct response is not automatically to accuse the laboratory of manipulation.

The correct response is to ask for the analytical method and raw data.

4. Are the Method Parameters Available?

A useful chromatogram should be accompanied by sufficient method information to understand the analysis.

Look for:

• Column type.
• Column dimensions.
• Mobile phase.
• Gradient.
• Flow rate.
• Temperature.
• Detection wavelength.
• Injection volume.
• Run time.

Without these details, reproducing or evaluating the method becomes difficult.

10 HPLC COA Red Flags Researchers Should Know

Here is a practical checklist.

COA Feature	Positive Indicator	Warning Sign
HPLC result	Full chromatogram provided	Only a percentage
Peak shape	Symmetrical and well resolved	Shoulder or severe tailing
Integration	Visible peaks accounted for	Unexplained missing integration
Method	Full parameters disclosed	Vague methodology
Identity	MS confirmation	Retention time alone
Laboratory	Verifiable laboratory	Anonymous “QC lab”
Lot number	Matches material tested	Generic report
Date	Specific test date	No testing date
Raw data	Available on request	Refusal to provide relevant data
Orthogonal testing	Used where justified	HPLC presented as universal proof

Why LC-MS/MS Is So Important

LC-MS/MS can answer questions that ordinary HPLC-UV cannot.

HPLC tells you about chromatographic behavior.

Mass spectrometry provides molecular-mass information.

Tandem MS can provide structural information through fragmentation.

This combination can help researchers:

• Identify unexpected masses.
• Detect co-eluting species.
• Characterize sequence-related impurities.
• Investigate degradation products.
• Confirm molecular identity.
• Compare observed and theoretical masses.

FDA research has demonstrated the value of LC-MS/MS for peptide impurity profiling, including identification of impurities that co-eluted with major peptide peaks.

High-resolution MS can provide even more accurate mass information.

However, it is important to understand that LC-MS does not solve every analytical problem automatically.

For example, some structural isomers can have the same molecular mass.

That is why analytical characterization should be based on complementary methods.

Orthogonal Testing: What Should Be Tested?

The best method depends on the suspected problem.

Potential Problem	Useful Analytical Approach
Chromatographic impurities	RP-HPLC / UHPLC
Molecular identity	LC-MS / HRMS
Sequence-related impurities	LC-MS/MS
Isobaric sequence variants	High-resolution MS/MS / appropriate fragmentation
Chiral variants	Chiral chromatography / amino-acid analysis
Deamidation/isomerization	Alternative chromatography + MS/MS
Aggregates	SEC / SEC-MALS
Counterions	Ion chromatography or appropriate quantitative methods
Residual solvents	GC-based analysis
Moisture	Karl Fischer titration
Heavy metals	ICP-MS
Endotoxin	Appropriate endotoxin assay
Amino-acid composition	Amino-acid analysis

The important principle is:

Do not choose analytical methods because they look impressive. Choose them because they answer a specific quality question.

Case Study: When a High HPLC Purity Result Is Not the Whole Story

One of the most useful ways to understand peptide impurities not detected by HPLC is to consider a degradation scenario involving deamidation.

A synthetic peptide can display a very strong principal peak by RP-HPLC.

Yet a structurally modified form may be present within that peak.

The analytical problem is not necessarily that the HPLC instrument is defective.

The issue is that the method may not provide enough selectivity to separate the related species.

The Analytical Question

Imagine a peptide containing a susceptible asparagine residue.

During storage, chemical modification occurs.

The native peptide and modified peptide have sufficiently similar chromatographic behavior that the conventional RP-HPLC method does not fully resolve them.

The chromatogram still looks clean.

The reported purity remains high.

But the molecular population has changed.

What Additional Testing Can Reveal

A combination of:

• Alternative chromatographic separation.
• High-resolution MS.
• Tandem MS.
• Targeted degradation analysis.
• Functional testing where scientifically justified.

can provide a more complete picture.

This principle is consistent with the broader pharmaceutical analytical literature: peptide impurities can require multiple complementary methods because structural modifications, aggregates, and related substances are not necessarily resolved by one chromatographic method.

Important distinction

A case like this should not be interpreted as proof that every high-HPLC-purity peptide is degraded.

The correct lesson is:

A single HPLC purity value cannot answer every peptide-quality question.

A Practical Tier-Based Peptide Testing Strategy

Researchers often ask:

“What testing should I actually request?”

There is no universal testing package for every peptide.

The appropriate analytical strategy depends on the peptide, intended application, synthesis route, formulation, stability risks and quality requirements.

Nevertheless, a practical tier system can help.

Tier 1: Basic Identity and Chromatographic Purity

At minimum, researchers should want:

RP-HPLC

Useful for:

• Relative chromatographic purity.
• Detectable related substances.
• Lot-to-lot comparison.
• Stability monitoring.

Mass Spectrometry

Useful for:

• Molecular identity.
• Molecular mass confirmation.
• Detection of unexpected species.

The combination is significantly more informative than HPLC alone.

Tier 2: Quantitative Composition

When accurate peptide concentration matters, consider additional testing for:

Moisture

Karl Fischer titration can quantify water.

Counterions

Ion chromatography or another appropriate quantitative method can help determine counterion content.

Net Peptide Content

Mass-balance approaches can provide a more realistic estimate of the peptide material present in a lyophilized vial.

USP’s work on peptide reference standards demonstrates the importance of combining multiple analytical measurements when assigning quantitative values to peptide materials.

Tier 3: Advanced Structural Characterization

Additional testing becomes increasingly valuable for:

• Long peptides.
• Modified peptides.
• Hydrophobic peptides.
• Cyclic peptides.
• Aggregation-prone peptides.
• Peptides with susceptible degradation sites.
• Custom sequences.
• Peptides containing unusual amino acids.

Possible methods include:

• HRMS.
• LC-MS/MS.
• SEC-MALS.
• HILIC.
• Chiral chromatography.
• Amino-acid analysis.
• Specialized fragmentation.
• Other validated orthogonal methods.

FDA guidance on peptide impurity studies specifically highlights orthogonal chromatographic methods and UHPLC-HRMS/MS for impurity identification and characterization.

How Researchers Can Evaluate a Peptide Supplier

A professional peptide supplier should not expect researchers to trust a single number.

The goal should be transparency.

Ask for the Lot-Specific COA

The COA should correspond to the exact lot being supplied.

A generic COA is much less useful.

Examine the Laboratory

If an independent laboratory is listed, verify that the laboratory exists and that its capabilities are consistent with the reported analysis.

ISO/IEC 17025 is an international standard addressing competence, impartiality and consistent operation of testing and calibration laboratories.

However, researchers should understand that accreditation does not mean every possible analytical method is automatically covered.

The relevant scope matters.

Ask for Orthogonal Evidence

If a supplier claims:

“99% HPLC purity.”

A better question is:

“How was identity confirmed?”

Then ask:

“What testing was performed beyond HPLC?”

The answer tells you much more about the supplier’s quality philosophy.

My Experience With Peptide Quality Control Since 2003

I have worked with peptides since 2003, and one lesson has remained consistent:

The number printed on a COA is only as meaningful as the analytical method behind it.

Over the years, I have worked with third-party laboratories and helped researchers interpret peptide analytical documentation.

One of the biggest recurring problems is that researchers are often trained to look for a single number.

They see:

98%

99%

99.5%

and assume that the highest number automatically represents the best material.

That is not how analytical chemistry works.

A 99.5% result generated by a poorly designed or poorly documented method can be less informative than a 98% result supported by:

• A complete chromatogram.
• Mass confirmation.
• Transparent methodology.
• Lot-specific documentation.
• Appropriate orthogonal testing.
• A traceable analytical laboratory.

This is why I encourage researchers to stop asking only:

“What is the purity percentage?”

and start asking:

“What exactly was measured?”

Then ask:

“What could this method have missed?”

That second question is often where real quality control begins.

What I Look for When Reviewing a Peptide COA

When helping researchers interpret peptide documentation, I recommend looking at the entire analytical story.

First: Identity

Is there evidence that the material is actually the intended peptide?

Second: Chromatographic Purity

Does the HPLC method show a clean, well-resolved chromatogram?

Third: Method Transparency

Are the column and analytical conditions disclosed?

Fourth: Related Substances

Are secondary peaks identified or at least accounted for?

Fifth: Quantitative Content

Does the reported amount account for water and counterions where appropriate?

Sixth: Stability

Has the material been evaluated under relevant storage conditions?

Seventh: Additional Contaminants

Where appropriate, are residual solvents, metals, endotoxin or other contaminants evaluated?

This approach gives researchers a much stronger quality-control framework than simply searching for “99%.”

Peptide Impurities Not Detected by HPLC: The Most Important Lesson

The central lesson is simple.

HPLC is a powerful analytical tool, but it is not a universal molecular truth detector.

A clean chromatogram does not automatically establish:

• Absolute molecular identity.
• Complete sequence correctness.
• Absence of structural isomers.
• Absence of aggregates.
• Absence of residual solvents.
• Absence of counterions.
• Absence of water.
• Absence of every degradation product.
• Exact net peptide content.

This is why researchers need to understand peptide impurities not detected by HPLC.

The answer is not to abandon HPLC.

The answer is to use HPLC intelligently.

HPLC should be combined with orthogonal analytical methods whenever the scientific question requires information that HPLC alone cannot provide.

FDA and USP materials both support the broader principle that comprehensive peptide characterization can require multiple analytical techniques, including chromatography, mass spectrometry and other orthogonal approaches.

Peptide Impurities Not Detected by HPLC: Final Researcher Checklist

Before accepting a peptide solely because the COA says “99% HPLC,” ask:

Identity

• Is the molecular identity confirmed by MS?
• Does the measured mass correspond to the intended peptide?
• Is sequence confirmation appropriate for the application?

HPLC

• Is the raw chromatogram available?
• Is the main peak symmetrical?
• Are there shoulders?
• Are all visible peaks integrated?
• Are method parameters provided?

Structural Impurities

• Could chiral variants be present?
• Could deamidation occur?
• Could oxidation occur?
• Could isobaric variants be present?

Physical State

• Could aggregates or oligomers be present?
• Is SEC or another orthogonal method appropriate?

Quantitative Content

• Has moisture been considered?
• Have counterions been characterized?
• Is net peptide content known?

Contaminants

• Are residual solvents relevant?
• Are heavy metals relevant?
• Is endotoxin testing relevant to the intended research application?

Laboratory

• Is the testing laboratory identifiable?
• Is its accreditation and scope verifiable?
• Does the report correspond to the actual lot?

If the answer to all of these questions is not necessarily “yes,” that does not automatically mean the peptide is poor quality.

It means you should understand what has been demonstrated—and what has not.

Frequently Asked Questions

1. Can HPLC miss peptide impurities?

Yes.

Conventional RP-HPLC can fail to adequately resolve or characterize certain peptide impurities, particularly co-eluting species, structural isomers, closely related degradation products and some aggregation-related species. FDA research has demonstrated that LC-MS/MS can identify peptide impurities that are not adequately resolved by conventional chromatographic approaches.

The important distinction is that HPLC does not necessarily “miss” an impurity because the instrument is defective. The impurity may simply have chromatographic behavior that prevents adequate separation or detection under the selected conditions.

2. Does 99% HPLC purity mean the peptide is 99% pure?

Not necessarily.

A reported HPLC purity percentage generally represents relative chromatographic peak area under the specified method.

It does not automatically represent the percentage of total vial mass that consists of the intended peptide.

Water, counterions and other non-chromatographic components may require separate quantitative analysis.

Therefore, researchers should distinguish between chromatographic purity, molecular identity and quantitative peptide content.

3. Can two different peptides have the same HPLC retention time?

Yes.

Retention time is influenced by chromatographic interactions.

Two chemically different species can sometimes have sufficiently similar interactions with the stationary and mobile phases to elute together.

That is why retention time alone is not considered definitive proof of molecular identity.

Orthogonal methods such as mass spectrometry can provide additional evidence.

4. Can mass spectrometry detect impurities that HPLC misses?

It can, depending on the impurity and analytical setup.

LC-MS and LC-MS/MS can provide molecular-mass and structural information that UV detection alone cannot provide.

FDA researchers have used LC-MS/MS to profile peptide impurities, including impurities associated with or co-eluting with major peptide peaks.

However, mass spectrometry also has limitations.

Some structural isomers can have identical or nearly identical masses.

Consequently, LC-MS should be viewed as an important component of orthogonal characterization rather than a universal replacement for chromatography.

5. What is the difference between peptide purity and peptide identity?

Purity asks how much of the detected chromatographic material corresponds to the principal component under a defined analytical method.

Identity asks whether that component is actually the intended peptide.

A sample can have an excellent chromatographic purity result while still requiring independent molecular confirmation.

That is why high-quality peptide characterization commonly combines chromatography and mass spectrometry.

6. Why are peptide aggregates difficult to detect by standard HPLC?

Aggregates can behave differently from individual peptide molecules.

Some may be separated.

Others may interact strongly with the chromatographic stationary phase, form insoluble material, or otherwise behave differently from the monomeric peptide.

For aggregation assessment, techniques such as size-exclusion chromatography can provide information that conventional RP-HPLC may not.

FDA guidance identifies size-exclusion chromatography as an appropriate approach for assessing aggregates in relevant peptide/protein analytical contexts.

7. What should I look for on a peptide HPLC COA?

Start with the chromatogram rather than the headline purity percentage.

Look for:

• Full chromatogram.
• Peak shape.
• Secondary peaks.
• Shoulders.
• Baseline behavior.
• Integration.
• Retention time.
• Detection wavelength.
• Column information.
• Gradient and flow conditions.
• Lot number.
• Testing date.
• Laboratory identity.

Then determine whether mass spectrometry or other orthogonal testing is available.

8. Is an HPLC-only COA automatically bad?

No.

The suitability of an analytical package depends on the intended purpose, peptide characteristics and quality requirements.

HPLC is a valuable and widely used analytical method.

The problem occurs when an HPLC result is presented as though it answers questions that the method was never designed to answer.

For routine chromatographic purity, HPLC can be highly useful.

For comprehensive structural characterization, additional techniques may be necessary.

9. Which peptides need more extensive characterization?

There is no single universal list.

However, additional characterization can become particularly important for:

• Long peptides.
• Hydrophobic peptides.
• Modified peptides.
• Cyclic peptides.
• Aggregation-prone peptides.
• Peptides susceptible to oxidation.
• Peptides susceptible to deamidation.
• Custom sequences.
• Peptides containing unusual or chiral amino-acid configurations.

The analytical strategy should be based on the molecule’s known risks and the purpose of the study.

10. What is the best way to avoid peptide impurities not detected by HPLC?

The best approach is not to eliminate HPLC.

Instead, use orthogonal analytical characterization.

A practical strategy can include:

HPLC → chromatographic purity

MS/HRMS → molecular identity

MS/MS → structural and sequence information

SEC/SEC-MALS → aggregation

Karl Fischer → moisture

Ion chromatography → counterions

GC-based testing → residual solvents

ICP-MS → trace metals

Other specialized methods → specific structural or contamination risks

The goal is to ensure that each important quality question is answered by an analytical method capable of answering it.

Final Thoughts: Don’t Let One Number Tell the Whole Story

The most important lesson I can give researchers after working with peptides since 2003 is this:

Never judge a peptide solely by the largest number printed on its COA.

A “99% HPLC purity” result can be useful.

But it is only useful when you understand what the analytical method actually measured.

The real quality question is broader:

Is this the correct peptide?

Is the peptide structurally intact?

Are related impurities adequately characterized?

Could degradation products be hiding within the main peak?

Could aggregates be present?

What percentage of the vial is actually peptide rather than water or counterion?

Are residual solvents or trace contaminants relevant?

Can the reported laboratory results be independently verified?

That is the difference between simply reading a COA and actually interpreting one.

At OasBioScience, our educational approach is built around helping researchers understand peptide quality documentation, analytical terminology and the limitations of individual testing methods rather than treating a single purity percentage as the entire quality story.

For additional peptide research and educational resources, you can visit OasBioScience.

Research responsibly. Verify identity. Understand the analytical method. Read the chromatogram. And never confuse one purity number with complete molecular characterization.

Continue Learning: If you found this guide helpful, you may also want to read our previous peptide education articles covering the following topics

• Does adding more diluent make peptides weaker?
• Peptide vendor documents explained
• Explore 9 evidence-based facts about BPC-157
• How long should a weight loss cycle last?
• Can GLP-1 muscle loss be prevented?
• Discover the best peptide for obesity research.
• Which peptide suppresses appetite the most?
• Discover 9 powerful fixes for peptide foaming
• Learn how to read peptide Certificates of Analysis step by step.
• How Should Peptides Be Stored?
• Learn the correct peptide reconstitution process 2026

• Does adding more diluent make peptides weaker?
• Learn 7 powerful reasons why, how HPLC methods affect results
• Peptides warmed in transit are not automatically ruined
• How long can peptides stay unrefrigerated during shipping?
• Learn the complete peptide synthesis and manufacturing process
• HPLC vs Mass Spectrometry explained
• Can I use sterile water instead of bacteriostatic water?
• A 99% HPLC result can look impressive—but what does it really tell you?
• Why won’t my peptide dissolve?
• Should you swirl or shake peptides after mixing?
• Our latest guide explains the best practices for storing lyophilized research peptide
• What questions you should ask a peptide supplier before ordering

Scientific Reference: For additional peer-reviewed information on peptide stability, sterile preparation, and pharmaceutical reconstitution practices, visit

PubMed

European Medicines Agency (EMA)

National Center for Biotechnology Information (NCBI)